BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 18809328)

  • 1. Optimization of a series of potent and selective ketone histone deacetylase inhibitors.
    Pescatore G; Kinzel O; Attenni B; Cecchetti O; Fiore F; Fonsi M; Rowley M; Schultz-Fademrecht C; Serafini S; Steinkühler C; Jones P
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5528-32. PubMed ID: 18809328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A series of novel, potent, and selective histone deacetylase inhibitors.
    Jones P; Altamura S; Chakravarty PK; Cecchetti O; De Francesco R; Gallinari P; Ingenito R; Meinke PT; Petrocchi A; Rowley M; Scarpelli R; Serafini S; Steinkühler C
    Bioorg Med Chem Lett; 2006 Dec; 16(23):5948-52. PubMed ID: 16987657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.
    Jones P; Altamura S; De Francesco R; Paz OG; Kinzel O; Mesiti G; Monteagudo E; Pescatore G; Rowley M; Verdirame M; Steinkühler C
    J Med Chem; 2008 Apr; 51(8):2350-3. PubMed ID: 18370373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
    Khan N; Jeffers M; Kumar S; Hackett C; Boldog F; Khramtsov N; Qian X; Mills E; Berghs SC; Carey N; Finn PW; Collins LS; Tumber A; Ritchie JW; Jensen PB; Lichenstein HS; Sehested M
    Biochem J; 2008 Jan; 409(2):581-9. PubMed ID: 17868033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and optimization of a binding assay for histone deacetylase 4 using surface plasmon resonance.
    Mattu M; Di Giovine P; Steinkuhler C; De Francesco R; Altamura S; Cecchetti O; Carfì A; Barbato G
    Anal Biochem; 2008 Jun; 377(2):267-9. PubMed ID: 18381195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model.
    Attenni B; Ontoria JM; Cruz JC; Rowley M; Schultz-Fademrecht C; Steinkühler C; Jones P
    Bioorg Med Chem Lett; 2009 Jun; 19(11):3081-4. PubMed ID: 19410459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chlamydocin analogs bearing carbonyl group as possible ligand toward zinc atom in histone deacetylases.
    Bhuiyan MP; Kato T; Okauchi T; Nishino N; Maeda S; Nishino TG; Yoshida M
    Bioorg Med Chem; 2006 May; 14(10):3438-46. PubMed ID: 16439135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha-mercaptoketone based histone deacetylase inhibitors.
    Wash PL; Hoffman TZ; Wiley BM; Bonnefous C; Smith ND; Sertic MS; Lawrence CM; Symons KT; Nguyen PM; Lustig KD; Guo X; Annable T; Noble SA; Hager JH; Hassig CA; Malecha JW
    Bioorg Med Chem Lett; 2008 Dec; 18(24):6482-5. PubMed ID: 18954984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2-Trifluoroacetylthiophenes, a novel series of potent and selective class II histone deacetylase inhibitors.
    Jones P; Bottomley MJ; Carfí A; Cecchetti O; Ferrigno F; Lo Surdo P; Ontoria JM; Rowley M; Scarpelli R; Schultz-Fademrecht C; Steinkühler C
    Bioorg Med Chem Lett; 2008 Jun; 18(11):3456-61. PubMed ID: 18440229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and biological activity of boronic acid-based histone deacetylase inhibitors.
    Suzuki N; Suzuki T; Ota Y; Nakano T; Kurihara M; Okuda H; Yamori T; Tsumoto H; Nakagawa H; Miyata N
    J Med Chem; 2009 May; 52(9):2909-22. PubMed ID: 19419205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of pyrimidyl-5-hydroxamic acids as new potent histone deacetylase inhibitors.
    Angibaud P; Arts J; Van Emelen K; Poncelet V; Pilatte I; Roux B; Van Brandt S; Verdonck M; De Winter H; Ten Holte P; Marien A; Floren W; Janssens B; Van Dun J; Aerts A; Van Gompel J; Gaurrand S; Queguiner L; Argoullon JM; Van Hijfte L; Freyne E; Janicot M
    Eur J Med Chem; 2005 Jun; 40(6):597-606. PubMed ID: 15922843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and evaluation of cyclic amide/imide-bearing hydroxamic acid derivatives as class-selective histone deacetylase (HDAC) inhibitors.
    Shinji C; Maeda S; Imai K; Yoshida M; Hashimoto Y; Miyachi H
    Bioorg Med Chem; 2006 Nov; 14(22):7625-51. PubMed ID: 16877001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel histone deacetylase inhibitors: cyclic tetrapeptide with trifluoromethyl and pentafluoroethyl ketones.
    Jose B; Oniki Y; Kato T; Nishino N; Sumida Y; Yoshida M
    Bioorg Med Chem Lett; 2004 Nov; 14(21):5343-6. PubMed ID: 15454224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and evaluation of lysine derived sulfamides as histone deacetylase inhibitors.
    Manku S; Allan M; Nguyen N; Ajamian A; Rodrigue J; Therrien E; Wang J; Guo T; Rahil J; Petschner AJ; Nicolescu A; Lefebvre S; Li Z; Fournel M; Besterman JM; Déziel R; Wahhab A
    Bioorg Med Chem Lett; 2009 Apr; 19(7):1866-70. PubMed ID: 19272776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thiol-based SAHA analogues as potent histone deacetylase inhibitors.
    Suzuki T; Kouketsu A; Matsuura A; Kohara A; Ninomiya S; Kohda K; Miyata N
    Bioorg Med Chem Lett; 2004 Jun; 14(12):3313-7. PubMed ID: 15149697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties.
    Kinzel O; Llauger-Bufi L; Pescatore G; Rowley M; Schultz-Fademrecht C; Monteagudo E; Fonsi M; Gonzalez Paz O; Fiore F; Steinkühler C; Jones P
    J Med Chem; 2009 Jun; 52(11):3453-6. PubMed ID: 19441846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring the pharmacokinetic properties of phosphorus-containing selective HDAC 1 and 2 inhibitors (SHI-1:2).
    Heidebrecht RW; Chenard M; Close J; Dahlberg WK; Fleming J; Grimm JB; Hamill JE; Harsch A; Haines BB; Hughes B; Kral AM; Middleton RE; Mushti C; Ozerova N; Szewczak AA; Wang H; Wilson K; Witter DJ; Secrist JP; Miller TA
    Bioorg Med Chem Lett; 2009 Apr; 19(7):2053-8. PubMed ID: 19268585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trithiocarbonates: exploration of a new head group for HDAC inhibitors.
    Dehmel F; Ciossek T; Maier T; Weinbrenner S; Schmidt B; Zoche M; Beckers T
    Bioorg Med Chem Lett; 2007 Sep; 17(17):4746-52. PubMed ID: 17606370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereoselective HDAC inhibition from cysteine-derived zinc-binding groups.
    Butler KV; He R; McLaughlin K; Vistoli G; Langley B; Kozikowski AP
    ChemMedChem; 2009 Aug; 4(8):1292-301. PubMed ID: 19551801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo.
    Weichert W; Röske A; Niesporek S; Noske A; Buckendahl AC; Dietel M; Gekeler V; Boehm M; Beckers T; Denkert C
    Clin Cancer Res; 2008 Mar; 14(6):1669-77. PubMed ID: 18347167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.